Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses ...

If you are wondering whether Haemonetics at around US$56.36 is starting to look attractively priced, the recent share performance gives you a lot to think about. The stock has seen a 0.5% decline over ...

Haemonetics (NYSE:HAE) announced today that it received FDA approval to expand the labeling for its Vascade MVP XL system.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

9 analysts have shared their evaluations of Haemonetics (NYSE:HAE) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

VASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologies BOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

Haemonetics (NYSE:HAE) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of their ...

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 ...

BOSTON, April 4, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced ...

In recent years, much of Haemonetics’ focus has been on building out a portfolio of devices for interventional cardiology procedures. Its latest M&A move continues that trend. The Boston-based ...